Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Bladder Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Bladder Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Breast Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
CONTESSA2: Ph2 HER2- HR+ BC View
Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
CONTESSA2: Ph2 HER2- HR+ BC View
Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
CONTESSA2: Ph2 HER2- HR+ BC View
Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
CONTESSA2: Ph2 HER2- HR+ BC View
Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Cervical Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Cervical Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Cervical Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Cervical Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Cervical Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph2 Cervical 2L (RaPiDS) View
Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)
Indication:
Cervical Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph2 Cervical 2L (RaPiDS) View
Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)
Indication:
Cervical Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph2 Cervical 2L (RaPiDS) View
Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)
Indication:
Cervical Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: II
Title:
Ph2 Cervical 2L (RaPiDS) View
Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)
Indication:
Cervical Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Colon Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Colon Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Colon Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Colon Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Endometrial Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Endometrial Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Esophageal Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Gastric Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Gastric Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Gastric Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Gastric Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Gastric Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ublituximab+TGR-1202 Cross-over View
Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
Indication:
Leukemia
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ublituximab+TGR-1202 Cross-over View
Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
Indication:
Leukemia
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ublituximab+TGR-1202 Cross-over View
Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
Indication:
Leukemia
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ublituximab+TGR-1202 Cross-over View
Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
Indication:
Leukemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ublituximab+TGR-1202 Cross-over View
Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
Indication:
Leukemia
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View
Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)
Indication:
Leukemia
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View
Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)
Indication:
Leukemia
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View
Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)
Indication:
Leukemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View
Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)
Indication:
Leukemia
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Liver Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Liver Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Liver Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Liver Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Liver Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Tepotinib stage IIIB/IV NSCLC w/ METex14 View
Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Tepotinib stage IIIB/IV NSCLC w/ METex14 View
Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Tepotinib stage IIIB/IV NSCLC w/ METex14 View
Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022
Indication:
Lung Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Tepotinib stage IIIB/IV NSCLC w/ METex14 View
Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Tepotinib stage IIIB/IV NSCLC w/ METex14 View
Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Lung Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph2 MGCDs+Nivo NSCLC View
Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph2 MGCDs+Nivo NSCLC View
Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph2 MGCDs+Nivo NSCLC View
Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)
Indication:
Lung Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ph2 MGCDs+Nivo NSCLC View
Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph2 MGCDs+Nivo NSCLC View
Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph2 Poziotinib EGFR/HER2 NSCLC View
Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Lung Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
STAR KEAP1/NRF2 NSCLC View
Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
STAR KEAP1/NRF2 NSCLC View
Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
STAR KEAP1/NRF2 NSCLC View
Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Indication:
Lung Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
STAR KEAP1/NRF2 NSCLC View
Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR KEAP1/NRF2 NSCLC View
Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Austin Central
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-South Austin
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Austin North Suite 120
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Austin North Suite 300
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Round Rock
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Central
Phase: II
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Texas Oncology-South Austin
Phase: II
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Texas Oncology-Round Rock
Phase: II
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
STAR Ph2 A+AVD +G-CSF or AOAD in CHL View
Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Indication:
Lymphomas
Location:
Texas Oncology-Austin Central
Phase: II
Title:
STAR Ph2 A+AVD +G-CSF or AOAD in CHL View
Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Indication:
Lymphomas
Location:
Texas Oncology-South Austin
Phase: II
Title:
STAR Ph2 A+AVD +G-CSF or AOAD in CHL View
Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Indication:
Lymphomas
Location:
Texas Oncology-Round Rock
Phase: II
Title:
STAR Ph2 A+AVD +G-CSF or AOAD in CHL View
Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR Ph2 A+AVD +G-CSF or AOAD in CHL View
Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph2 T-Vec + Pembro Met Melanoma View
Description: (Amgen 20180115) Phase 2 Study of Talimogene Laherparepvec in Combination with Pembrolizumab in Subjects with Unresectable/Metastatic Stage IIIB-IVM1d Melanoma who have Progressed on Prior Anti-PD-1 Based Therapy
Indication:
Melanoma
Location:
Texas Oncology-Austin Central
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Ovarian Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Ovarian Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: II
Title:
CheckMate 848: Ph2 Nivo+Ip